menu
    • menu
    [{"orgOrder":0,"company":"Silk Road Therapies","sponsor":"Soligenix","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Pentoxifylline","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Silk Road Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Silk Road Therapies \/ Soligenix","highestDevelopmentStatusID":"8","companyTruncated":"Silk Road Therapies \/ Soligenix"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Pentoxifylline","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Silk Road Therapies","sponsor":"Poolbeg Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Pentoxifylline","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Silk Road Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Silk Road Therapies \/ Poolbeg Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Silk Road Therapies \/ Poolbeg Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Pentoxifylline

    Menu

    Pentoxifylline

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Silk Road Therapies

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Silk Road Therapies

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Poolbeg Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate

                            Details : Through the agreement with Silk Road Therapeutics to acquire novel topical muco-adherent formulation of Trental (pentoxifylline), for oral ulcers in patients suffering from behcet's disease.

                            Brand Name : Trental

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 30, 2024

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Poolbeg Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ANI Pharmaceuticals Inc

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            ANI Pharmaceuticals Inc

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

                            Details : Trental-Generic (pentoxifylline) is an oral small molecule drug. It is now approved for the treatment of chronic occlusive arterial disease of the limbs.

                            Brand Name : Trental-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 23, 2024

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Silk Road Therapies

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Silk Road Therapies

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Soligenix

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifyll...

                            Details : The option agreement grants Soligenix the right to acquire a novel topical formulation of SRT001 (pentoxifylline), a non-biological anti-TNF-alpha inhibitor, for the treatment of mucocutaneous ulcers in patient's suffering from Behçet's Disease (BD).

                            Brand Name : SRT001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 01, 2023

                            Lead Product(s) : Pentoxifylline

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Soligenix

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth